Study design
IBS
This trial was designed and conducted as a randomized, double-blinded, placebo-controlled trial, from February to April 2022, in the gastroenterology clinic of Imam Reza hospital in Tabriz city. In this trial, IBS patients were randomized in a 1:1 ratio to receive 6 mg of melatonin treatment (3 mg fasting and 3 mg at bedtime) or placebo for 8 weeks (2 months). They were evaluated both at the beginning and the end of the trial regarding IBS score, GI symptoms, quality of life, and sleep parameters Flow chart of the trial process